Acute myocardial infarction (AMI) continues to be a primary cause of post-hospitalization heart failure (HF), severely impacting morbidity, healthcare resource consumption, and mortality rates. This meta-analysis sought to assess the efficacy and safety of the early introduction of SGLT2 inhibitors in patients hospitalized for AMI, irrespective of previous HF or diabetes history. Up until June 10, 2025, a comprehensive search was carried out in six major databases, including randomized controlled trials (RCTs) assessing SGLT2i that were started within 14 days of hospitalization for AMI. Seven randomized controlled trials (n = 11,405) comparing SGLT2i with placebo or standard medical therapy without SGLT2i, with follow-up ranging from 6 to 18 months, were included. The commencement of SGLT2 inhibitors markedly diminished the likelihood of HF hospitalization (OR = 0.71; 95%CI: 0.58-0.86; P = 0.004). No notable changes were detected in all-cause mortality (OR = 1.05; 95%CI: 0.77-1.43), cardiovascular mortality (OR = 1.04; 95%CI: 0.83-1.30), major adverse cardiovascular events (MACE) (OR = 0.94; 95%CI: 0.85-1.05), recurrent myocardial infarction (OR = 1.12; 95%CI: 0.73-1.72), or stroke (OR = 0.58; 95%CI: 0.26-1.27). Early initiation of SGLT2i post-AMI significantly reduces the risk of subsequent HF hospitalization without increasing adverse events. However, no mortality benefit was observed. These findings support the selective use of SGLT2i in post-AMI patients at high risk of HF, while highlighting the need for further large-scale trials to assess long-term outcomes and refine patient selection.
Kurek et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: